Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have received an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $30.00.

EYPT has been the topic of several research analyst reports. HC Wainwright boosted their price target on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Mizuho set a $28.00 target price on Eyepoint Pharmaceuticals in a research note on Monday, October 20th. Chardan Capital reaffirmed a “buy” rating and issued a $27.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Royal Bank Of Canada lifted their price target on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, October 8th.

Eyepoint Pharmaceuticals Price Performance

NASDAQ EYPT opened at $11.99 on Friday. The firm has a market capitalization of $992.62 million, a price-to-earnings ratio of -4.47 and a beta of 1.85. The company has a 50 day simple moving average of $12.82 and a 200-day simple moving average of $10.39. Eyepoint Pharmaceuticals has a 52-week low of $3.91 and a 52-week high of $14.91.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. The company had revenue of $0.97 million for the quarter, compared to analysts’ expectations of $3.33 million. On average, analysts predict that Eyepoint Pharmaceuticals will post -2.13 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of EYPT. Dimensional Fund Advisors LP raised its holdings in shares of Eyepoint Pharmaceuticals by 227.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 229,087 shares of the company’s stock valued at $3,261,000 after purchasing an additional 159,125 shares in the last quarter. Fox Run Management L.L.C. bought a new position in Eyepoint Pharmaceuticals during the third quarter valued at about $185,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Eyepoint Pharmaceuticals by 59.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,082 shares of the company’s stock worth $314,000 after buying an additional 8,261 shares during the last quarter. Levin Capital Strategies L.P. boosted its stake in shares of Eyepoint Pharmaceuticals by 52.6% during the 3rd quarter. Levin Capital Strategies L.P. now owns 29,000 shares of the company’s stock worth $413,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Essex Investment Management Co. LLC boosted its stake in shares of Eyepoint Pharmaceuticals by 3.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 127,789 shares of the company’s stock worth $1,820,000 after acquiring an additional 4,098 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.